Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,598 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,598 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the completion of the transaction, the executive vice president owned 36,606 shares in the company, valued at approximately $11,993,955.90. This trade represents a 4.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Tolga Tanguler also recently made the following trade(s):

• On Friday, February 13th, Tolga Tanguler sold 1,959 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $310.08, for a total value of $607,446.72.
• On Monday, January 12th, Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.87, for a total value of $547,933.70.

Alnylam Pharmaceuticals Trading Down 0.2%

Shares of Alnylam Pharmaceuticals stock traded down $0.80 on Thursday, reaching $326.50. 74,844 shares of the company were exchanged, compared to its average volume of 1,448,643. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm has a market capitalization of $43.30 billion, a price-to-earnings ratio of 190.94 and a beta of 0.36. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The stock has a fifty day moving average price of $355.63 and a 200-day moving average price of $416.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.65) EPS. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ALNY. Root Financial Partners LLC purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $27,000. MV Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Finally, HM Payson & Co. bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $27,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on ALNY shares. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective for the company. Wells Fargo & Company reduced their target price on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a report on Tuesday, January 20th. Truist Financial lowered their price target on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Finally, Chardan Capital decreased their price objective on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Strategic research collaboration with Tenaya Therapeutics to discover cardiovascular genetic targets; deal includes up to $10M in upfront payments plus research funding and up to $1.13B in milestones — expands Alnylam’s RNAi target pipeline into cardiovascular disease and could add high?value, long?term opportunities. Tenaya collaboration
• Positive Sentiment: Reported reimbursement win and favorable trial progress noted in recent coverage — improves near?term commercial visibility for approved RNAi drugs and supports the view that current valuation may underprice upcoming revenue drivers. Reimbursement and trial progress
• Positive Sentiment: Industry tailwind: a large orphan?drug market outlook reinforces long?term demand for Alnylam’s rare?disease franchises, supporting sustained growth potential for marketed and pipeline RNAi therapies. Orphan?drug market
• Neutral Sentiment: Former Alnylam CEO John Maraganore joined Protego Biopharma’s board — notable industry movement but not directly material to Alnylam’s operations. Maraganore appointment
• Neutral Sentiment: Short?interest data reported as zero shares appears to be a reporting glitch (days?to?cover shown as 0.0); unlikely to be a real driver of positioning today.
• Negative Sentiment: Significant insider selling by the CEO and multiple EVPs (sales reported March 2–3, including CEO Yvonne Greenstreet and several senior execs); while insiders retain large holdings, the clustered sales (disclosed proceeds in the low?millions) can create near?term negative sentiment and selling pressure. CEO SEC filing InsiderTrades summary

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.